Leconotide | CAS# 247207-64-3 | calcium channel blocker, antihyperalgesia

MedKoo Cat#: 413213 | Name: Leconotide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Leconotide is a calcium channel blocker and antihyperalgesia agent; isolated from the venom of the cone snail, Conus catus.

Chemical Structure

Leconotide

CAS#247207-64-3

Theoretical Analysis

MedKoo Cat#: 413213

Name: Leconotide

CAS#: 247207-64-3

Chemical Formula: C107H179N35O36S7

Exact Mass: 2754.1297

Molecular Weight: 2756.24

Elemental Analysis: C, 46.63; H, 6.55; N, 17.79; O, 20.90; S, 8.14

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Leconotide; AM 336; AM336; AM-336; CNSB-004; CNSB 004; CNSB004

IUPAC/Chemical Name

(6S,12S,15S,21S,24R,27S,33S,36R,39R,42S)-1-amino-6-(((R)-1-amino-1-oxo-3-thioxopropan-2-yl)carbamoyl)-42-((2S,5S,8S,11S,14S,17R,20S,23S,29S,32S,35S,38R)-38-amino-11,20,29,35-tetrakis(4-aminobutyl)-2-(4-hydroxybenzyl)-14,32-bis(hydroxymethyl)-8-isobutyl-39-mercapto-17-(mercaptomethyl)-23-methyl-5-(2-(methylthio)ethyl)-4,7,10,13,16,19,22,25,28,31,34,37-dodecaoxo-3,6,9,12,15,18,21,24,27,30,33,36-dodecaazanonatriacontanamido)-15-((R)-1-hydroxyethyl)-21,27,33-tris(hydroxymethyl)-1-imino-12-isopropyl-39-(mercaptomethyl)-8,11,14,17,20,23,26,29,32,35,38,41-dodecaoxo-24,36-dithioformyl-2,7,10,13,16,19,22,25,28,31,34,37,40-tridecaazatetratetracontan-44-oic acid

InChi Key

HBMCYCKNGADUQP-CFIKXUEXSA-N

InChi Code

InChI=1S/C107H179N35O36S7/c1-51(2)33-64(129-91(163)62(20-11-15-30-111)127-100(172)71(44-147)135-103(175)73(47-181)137-93(165)60(18-9-13-28-109)124-85(157)53(5)121-77(150)36-117-87(159)58(17-8-12-27-108)126-99(171)70(43-146)134-92(164)61(19-10-14-29-110)125-86(158)57(112)45-179)95(167)128-63(26-32-185-7)94(166)130-65(34-55-22-24-56(149)25-23-55)96(168)131-66(35-81(154)155)97(169)138-76(50-184)104(176)140-75(49-183)102(174)133-67(40-143)88(160)118-37-79(152)123-69(42-145)98(170)139-74(48-182)101(173)132-68(41-144)89(161)119-39-80(153)141-83(54(6)148)106(178)142-82(52(3)4)105(177)120-38-78(151)122-59(21-16-31-116-107(114)115)90(162)136-72(46-180)84(113)156/h22-25,46,48-49,51-54,57-76,82-83,143-149,179,181,184H,8-21,26-45,47,50,108-112H2,1-7H3,(H2,113,156)(H,117,159)(H,118,160)(H,119,161)(H,120,177)(H,121,150)(H,122,151)(H,123,152)(H,124,157)(H,125,158)(H,126,171)(H,127,172)(H,128,167)(H,129,163)(H,130,166)(H,131,168)(H,132,173)(H,133,174)(H,134,164)(H,135,175)(H,136,162)(H,137,165)(H,138,169)(H,139,170)(H,140,176)(H,141,153)(H,142,178)(H,154,155)(H4,114,115,116)/t53-,54+,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,82-,83-/m0/s1

SMILES Code

CSCC[C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N)=O)C=S)=O)CCCNC(N)=N)=O)=O)C(C)C)=O)[C@H](O)C)=O)=O)CO)=O)C=S)=O)CO)=O)=O)CO)=O)C=S)=O)CS)=O)CC(O)=O)=O)Cc1ccc(O)cc1)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CS)N)=O)CCCCN)=O)CO)=O)CCCCN)=O)=O)C)=O)CCCCN)=O)CS)=O)CO)=O)CCCCN)=O)CC(C)C)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 2,756.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Bruel BM, Burton AW. Intrathecal Therapy for Cancer-Related Pain. Pain Med. 2016 Dec;17(12):2404-2421. doi: 10.1093/pm/pnw060. Epub 2016 Apr 28. PMID: 28025375; PMCID: PMC5654346. 2: Zamponi GW, Striessnig J, Koschak A, Dolphin AC. The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential. Pharmacol Rev. 2015 Oct;67(4):821-70. doi: 10.1124/pr.114.009654. PMID: 26362469; PMCID: PMC4630564. 3: Deer TR, Pope JE, Hanes MC, McDowell GC. Intrathecal Therapy for Chronic Pain: A Review of Morphine and Ziconotide as Firstline Options. Pain Med. 2019 Apr 1;20(4):784-798. doi: 10.1093/pm/pny132. PMID: 30137539; PMCID: PMC6442748. 4: Kolosov A, Goodchild CS, Cooke I. CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain. Pain Med. 2010 Feb;11(2):262-73. doi: 10.1111/j.1526-4637.2009.00741.x. Epub 2009 Nov 25. PMID: 20002322. 5: Wie CS, Derian A. Ziconotide. 2020 Jul 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. PMID: 29083772. 6: Kolosov A, Aurini L, Williams ED, Cooke I, Goodchild CS. Intravenous injection of leconotide, an omega conotoxin: synergistic antihyperalgesic effects with morphine in a rat model of bone cancer pain. Pain Med. 2011 Jun;12(6):923-41. doi: 10.1111/j.1526-4637.2011.01118.x. Epub 2011 May 3. PMID: 21539704. 7: Dupoiron D. Intrathecal therapy for pain in cancer patients. Curr Opin Support Palliat Care. 2019 Jun;13(2):75-80. doi: 10.1097/SPC.0000000000000427. PMID: 30896454. 8: Viswanath O, Urits I, Burns J, Charipova K, Gress K, McNally A, Urman RD, Welschmeyer A, Berger AA, Kassem H, Sanchez MG, Kaye AD, Eubanks TN, Cornett EM, Ngo AL. Central Neuropathic Mechanisms in Pain Signaling Pathways: Current Evidence and Recommendations. Adv Ther. 2020 May;37(5):1946-1959. doi: 10.1007/s12325-020-01334-w. Epub 2020 Apr 10. PMID: 32291648; PMCID: PMC7467462. 9: Deer TR, Pope JE, Hayek SM, Lamer TJ, Veizi IE, Erdek M, Wallace MS, Grider JS, Levy RM, Prager J, Rosen SM, Saulino M, Yaksh TL, De Andrés JA, Abejon Gonzalez D, Vesper J, Schu S, Simpson B, Mekhail N. The Polyanalgesic Consensus Conference (PACC): Recommendations for Intrathecal Drug Delivery: Guidance for Improving Safety and Mitigating Risks. Neuromodulation. 2017 Feb;20(2):155-176. doi: 10.1111/ner.12579. Epub 2017 Jan 2. PMID: 28042914. 10: Strigenz T. Ziconotide. J Pain Palliat Care Pharmacother. 2014 Mar;28(1):73-4. doi: 10.3109/15360288.2013.864749. Epub 2014 Jan 7. PMID: 24397285.